04:36:28 EDT Thu 18 Jul 2024
Enter Symbol
or Name
USA
CA



Q:CLDX - CELLDEX THERAPEUTICS INC - http://www.celldextherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CLDX - Q1.037.65·52.000.138.78-1.20-3.0540.920,6395,36839.59  39.88  38.1553.18  22.11Jul 17Jul 1615 min RT 2¢

Recent Trades - Last 10 of 5368
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-16 08:01U:CLDXNews ReleaseCelldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
2024-06-04 16:01U:CLDXNews ReleaseCelldex Therapeutics to Present at Jefferies Healthcare Conference
2024-06-02 09:01U:CLDXNews ReleaseCelldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
2024-05-15 08:01U:CLDXNews ReleaseCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
2024-05-06 16:01U:CLDXNews ReleaseCelldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-17 08:01U:CLDXNews ReleaseCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
2024-03-08 07:00U:CLDXNews ReleaseCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2024-03-05 10:30U:CLDXNews ReleaseCelldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
2024-03-05 10:11U:CLDXNews ReleaseCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-02-29 21:15U:CLDXNews ReleaseCelldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
2024-02-28 16:01U:CLDXNews ReleaseCelldex Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-26 07:01U:CLDXNews ReleaseCelldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2024-02-24 14:05U:CLDXNews ReleaseCelldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2024-02-06 16:01U:CLDXNews ReleaseCelldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-02-05 08:01U:CLDXNews ReleaseCelldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
2023-11-27 16:15U:CLDXNews ReleaseCelldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
2023-11-07 23:15U:CLDXNews ReleaseCelldex Therapeutics Announces Pricing of Public Offering of Common Stock
2023-11-07 16:01U:CLDXNews ReleaseCelldex Therapeutics Announces Proposed Public Offering of Common Stock
2023-11-06 06:30U:CLDXNews ReleaseCelldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2023-11-05 15:00U:CLDXNews ReleaseCelldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab